Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Aetna    AET

AETNA (AET)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Goldman M&A head Sykes joins management committee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 11:07pm CEST

(Reuters) - Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

(Reuters) - Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

The 54-year-old investment banker joins 28 other executives on the powerful committee, which includes Chief Executive Lloyd Blankfein and Chief Operating Officer Gary Cohn, and influences decisions about Goldman's business strategy and operations.

Sykes' appointment comes just nine days after the departure of another prominent Goldman banker, Yoel Zaoui, was announced in a separate internal memo. Zaoui shared the title of M&A co-head with Sykes and had also been on the management committee.

Sykes, who is based in Los Angeles, is also chairman of the global technology, media and telecommunications department of the investment banking division. He is a member of Goldman's internal Business Standards Committee.

The Goldman veteran joined the firm in 1984 and became a partner in 1992. He has advised on several high-profile deals, including Walt Disney Co's (>> The Walt Disney Company) acquisition of Pixar, Aetna Inc's (>> Aetna Inc.) acquisition of U.S. Healthcare and Roche Holding AG acquisition of Genentech.

"Gene has played a vital role in strengthening our investment banking franchise, particularly with respect to many of the most significant companies in technology and media," Blankfein and Cohn said in the memo, whose contents were confirmed by a spokesman.

(Reporting By Lauren Tara LaCapra in New York; editing by Andre Grenon)

By Lauren Tara LaCapra

Stocks mentioned in the article
ChangeLast1st jan.
AETNA 0.28% 176.92 Delayed Quote.-1.59%
GOLDMAN SACHS GROUP -0.87% 251.96 Delayed Quote.-0.44%
ROCHE HOLDING LTD. -0.39% 215.65 Delayed Quote.-12.17%
WALT DISNEY COMPANY (THE) -0.64% 100.24 Delayed Quote.-5.86%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AETNA
04/17AETNA INC /PA/ : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
04/17AETNA : to Release First-Quarter 2018 Results; Announces Business Segment Realig..
BU
04/17UnitedHealth earnings ease investor worries over flu season, stock up
RE
04/12AETNA : and Harvard T.H. Chan School of Public Health Launch Five-Year Well-Bein..
AQ
04/12CVS HEALTH : releases prescription savings finder tool
AQ
04/12LORI VAVRINEC : Making A Difference In Healthcare
AQ
04/11CVS to Help Patients Find Cheaper Drugs
DJ
04/11AETNA : Ex-dividend day for
FA
04/07AETNA : confident of healthy revenue hike
AQ
04/03SAKS FIFTH AVENUE CUSTOMER INFO HACK : 5 other major data breaches in 2018
AQ
More news
News from SeekingAlpha
04/17Fixing Drug Costs 
04/16Health insurers/managed care firms up ahead of UNH Q1 earnings tomorrow 
04/11CVS, The Right Prescription For A Trade War? 
04/11BRUNCH, CRAFT BEER, AND INVESTING : A Turning Point 
04/08HEALTHCARE : Eating You Alive 
Financials ($)
Sales 2018 61 474 M
EBIT 2018 4 863 M
Net income 2018 3 380 M
Debt 2018 -
Yield 2018 1,04%
P/E ratio 2018 17,15
P/E ratio 2019 15,24
Capi. / Sales 2018 0,94x
Capi. / Sales 2019 0,89x
Capitalization 58 077 M
Chart AETNA
Duration : Period :
Aetna Technical Analysis Chart | AET | US00817Y1082 | 4-Traders
Technical analysis trends AETNA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 204 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Mark T. Bertolini Chairman & Chief Executive Officer
Karen S. Lynch President
Margaret M. McCarthy Executive Vice President-Operations & Technology
Shawn M. Guertin CFO, Executive VP & Chief Enterprise Risk Officer
Harold L. Paz Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AETNA-1.59%58 077
UNITEDHEALTH GROUP7.23%228 756
ANTHEM INC2.00%59 012
CIGNA-13.73%42 549
HUMANA20.25%41 071
CENTENE CORPORATION11.24%19 640